– The study investigated the clinical features, risk factors, and prognosis of intraocular recurrence in primary vitreoretinal lymphoma (PVRL).
– The study included 51 patients with PVRL, of which 14 patients experienced intraocular recurrence.
– The recurrence rate of intraocular involvement in PVRL was found to be 27.5% over a mean follow-up period of 42.5 months.
– There was no significant difference in the central nervous system lymphoma (CNSL) relapse rate and median time to CNSL between the intraocular non-recurrence and intraocular recurrence groups.
– There was also no significant difference in survival outcomes, such as mortality rate and median overall survival, between the two groups.
– Younger onset age, isolated PVRL, and no history of intravitreal chemotherapy were identified as independent risk factors for intraocular recurrences.
– Approximately 23.6% of patients with intraocular recurrence were asymptomatic and were diagnosed during routine follow-up.
– The rate of interleukin-10 (IL-10)/IL-6>1 was significantly lower at recurrence compared to the initial diagnosis, but the rate of IL-10≥50 pg/mL was high and not significantly different.
– The study suggests that intraocular recurrence does not have a significant impact on CNS manifestations or survival outcomes in patients with PVRL.
– Younger patients have a higher risk of intraocular recurrence, and combined systemic and intravitreal chemotherapy may reduce intraocular recurrence.
– Regular ophthalmic follow-up and IL-10 testing are recommended to detect intraocular recurrence.
Webpage address: Liu, Shixue, et al. “Prognosis, Risk Factors and Clinical Features of Intraocular Recurrence in Primary Vitreoretinal Lymphoma.” Ophthalmology Retina, vol. 0, no. 0, 31 Oct. 2023, doi:10.1016/j.oret.2023.10.021.